These increases in heart rate are more pronounced in the longer-acting GLP-1 agonists such as semaglutide and tirzepatide. Aside from heart conditions, you should also avoid semaglutide if you have any of the following conditions or situations: Type 1 diabetes mellitus A history of medullary thyroid carcinoma (MTC) Chronic stomach problems Eye disease or vision problems Medical history of pancreatitis Hypersensitivity to the drugs or its active ingredients Severe gastrointestinal diseases Kidney disease Are pregnant or breastfeeding If you have a pre-existing heart condition, please notify your healthcare provider so that they can decide whether semaglutide is a safe medication for you
Common Prior Authorization Criteria BMI documentation: Most states require a documented BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea) Failed lifestyle modification: Typically 3 to 6 months of documented dietary counseling and physical activity recommendations that did not produce adequate weight loss Step therapy: Some states require patients to try and fail less expensive medications (phentermine, orlistat) before approving GLP-1 coverage Provider qualification: Some Medicaid plans require the prescriber to have completed training in obesity medicine
In the search for ever more effective medicine, new, different compounds are being trialed that are seemingly leading to even more weight loss, said Belluz
FDA: Concern Over Compounded GLP-1 Drugs Important Medical Information and Disclaimers Medical Disclaimer This information is for educational use only
Prescribed For Flexible Dosing/Titration Not Achievable With Commercial Product
Within our bodies, vitamin C is tightly regulated
